Asosiy kontentga oʻtish
← Ishga qaytish

Ushbu ish iqtibos qilgan ishlar

159 ta ish

Ish: PCSK9 pathway-noncoding RNAs crosstalk: Emerging opportunities for novel therapeutic approaches in inflammatory atherosclerosis

  1. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

    Paul M. Ridker, Brendan M. Everett, Tom Thurén +25

    MaqolaOchiq kirish20177 iqtibos
    ABI
  2. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction

    Jean‐Claude Tardif, Simon Kouz, David D. Waters +22

    MaqolaOchiq kirish20193 iqtibos
    ABI
  3. Colchicine in Patients with Chronic Coronary Disease

    Stefan M. Nidorf, Aernoud T.L. Fiolet, Arend Mosterd +30

    MaqolaOchiq kirish20202 iqtibos
    ABI
  4. PCSK9 and LDLR degradation

    Thomas A. Lagace

    Sharh maqolaOchiq kirish20142 iqtibos
    ABI
  5. Sarlavhasiz

    Boshqa2 iqtibos
    ABI
  6. PCSK9 induces a pro-inflammatory response in macrophages

    Chiara Ricci, Massimiliano Ruscica, Marina Camera +10

    MaqolaOchiq kirish20182 iqtibos
    ABI
  7. The role of long noncoding RNA in major human disease

    Xiaoli Zhang, Ruiyun Hong, Weiqiang Chen +2

    Sharh maqola20192 iqtibos
    ABI
  8. Sarlavhasiz

    BoshqaOchiq kirish2 iqtibos
    ABI
  9. Proprotein Convertase Subtilisin/Kexin Type 9

    Chiara Macchi, Nicola Ferri, Cesare R. Sirtori +3

    Sharh maqolaOchiq kirish20212 iqtibos
    ABI
  10. Targeting inflammation in atherosclerosis — from experimental insights to the clinic

    Oliver Soehnlein, Peter Libby

    Sharh maqolaOchiq kirish20212 iqtibos
    ABI
  11. How the immune system shapes atherosclerosis: roles of innate and adaptive immunity

    Payel Roy, Marco Orecchioni, Klaus Ley

    Sharh maqolaOchiq kirish20212 iqtibos
    ABI
  12. PCSK9-targeted therapies: present and future approaches

    Mahmoud Al Rifai, Christie M. Ballantyne

    Sharh maqola20212 iqtibos
    ABI
  13. Inflammation and atherosclerosis: signaling pathways and therapeutic intervention

    Peng Kong, Ziyang Cui, Xiao-Fu Huang +3

    Sharh maqolaOchiq kirish20222 iqtibos
    ABI
  14. Sarlavhasiz

    Boshqa2 iqtibos
    ABI
  15. Sarlavhasiz

    Boshqa1 iqtibos
    ABI
  16. Sarlavhasiz

    BoshqaOchiq kirish1 iqtibos
    ABI
  17. Sarlavhasiz

    BoshqaOchiq kirish1 iqtibos
    ABI
  18. Sarlavhasiz

    BoshqaOchiq kirish1 iqtibos
    ABI